GlassScriptPhysician profile
Emily Heymann
NPI 1518335223
$4,023.76
in general payments reported to CMS, 2019-2025
44 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.92 · 2022: $580 · 2023: $1,485 · 2024: $1,446 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,207 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,206.94 |
| Education | $138.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $336.72 | 2021-2025 | Enhertu, Imfinzi, Calquence |
| Merck Sharp & Dohme LLC | $287.67 | 2023-2024 | Keytruda, Welireg |
| Celgene Corporation | $274.38 | 2022-2025 | Reblozyl, Pomalyst |
| Cti Biopharma Corp. | $245.81 | 2022-2023 | Vonjo |
| Glaxosmithkline, LLC. | $244.61 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Abbvie INC. | $199.41 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $166.43 | 2023-2024 | Libtayo |
| Lilly USA, LLC | $153.65 | 2022-2023 | Retevmo, Jaypirca, Verzenio |
| Kite Pharma, INC. | $141.48 | 2024-2025 | Yescarta |
| Gilead Sciences, INC. | $125.15 | 2023-2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $123.60 | 2022-2023 | Imbruvica |
| Adaptive Biotechnologies Corporation | $111.51 | 2022 | |
| Novartis Pharmaceuticals Corporation | $107.65 | 2022-2024 | |
| Janssen Biotech, INC. | $101.01 | 2023-2025 | Darzalex, Talvey, Tecvayli |
| Ipsen Biopharmaceuticals, INC | $100.96 | 2024 | Onivyde |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $99.39 | 2024-2025 | |
| Genentech USA, INC. | $90.91 | 2022-2025 | Venclexta, Perjeta, Kadcyla |
| Astellas Pharma US INC | $88.25 | 2022-2024 | Xospata, Cresemba |
| Aveo Pharmaceuticals, INC. | $85.90 | 2023-2024 | Fotivda |
| Incyte Corporation | $82.69 | 2024-2025 | Jakafi, Niktimvo |
| Rigel Pharmaceuticals, INC. | $75.10 | 2023-2024 | Tavalisse, Rezlidhia |
| Jazz Pharmaceuticals INC. | $62.61 | 2023-2024 | |
| Eisai INC. | $58.66 | 2023-2024 | |
| Pfizer INC. | $58.10 | 2023-2024 | |
| Daiichi Sankyo INC. | $54.32 | 2024-2025 | Enhertu |
| Pharmaessentia USA Corporation | $50.63 | 2024 | Besremi |
| Mirati Therapeutics, INC. | $50.18 | 2023-2024 | Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $49.01 | 2022-2023 | Alunbrig |
| Amgen INC. | $42.60 | 2023 | Kyprolis |
| Taiho Oncology, INC. | $41.71 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $30.65 | 2025 | Ultomiris |
| Servier Pharmaceuticals LLC | $30.16 | 2023 | |
| Sobi, INC | $25.93 | 2023 | |
| Pharmacosmos Therapeutics INC. | $24.73 | 2024 | Cosela |
| Karyopharm Therapeutics INC. | $23.57 | 2022 | |
| Genmab U.S., INC. | $22.48 | 2023 | Epkinly |
| E.R. Squibb & Sons, L.L.C. | $22.13 | 2024 | Opdivo |
| Exelixis INC. | $21.20 | 2023 | Cabometyx |
| Array Biopharma INC | $20.75 | 2024 | Xalkori, Lorbrena, Braftovi |
| Adc Therapeutics America, INC. | $20.66 | 2023 | |
| Morphosys, US INC. | $19.81 | 2023 | Monjuvi |
| Seagen INC. | $19.14 | 2023 | Tivdak |
| Beigene USA, INC. | $17.24 | 2025 | Brukinsa |
| Sun Pharmaceutical Industries INC. | $15.21 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Heymann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.